Effect of prucalopride on symptoms of chronic constipation
Authors:
Open Access
- 20 September 2013
- journal article
- research article
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 26 (1) , 21-27
Abstract
Background: Prucalopride is a 5‐HT4 receptor agonist with gastrointestinal prokinetic activities. This integrated analysis of data from three 12‐week, double‐blind trials evaluated the effect of prucalopride 2 mg q.d. on common constipation symptoms in women in whom laxatives had failed to provide adequate relief. The effect of prucalopride on bowel function was outside the scope of the analysis and has been described elsewhere.Methods: Women with self‐reported inadequate relief from laxatives and included in the prucalopride 2 mg or placebo arm of the trials were selected for analysis. Symptom severity was determined with the Patient Assessment of Constipation Symptoms (PAC–SYM) questionnaire. Observed changes from baseline in individual item scores were also evaluated by calculating Cohen's D effect sizes using baseline standard deviation (SD) (>0.2–0.5, >0.5–0.8 and >0.8 for small, moderate and large effects, respectively).Key Results: Data were analyzed for 936 women. The proportion of women with a PAC‐SYM severity score >2 at baseline was 50.0% for abdominal symptoms, 71.4% for stool symptoms, and 15.5% for rectal symptoms. Excluding the women without presence of a symptom at baseline from the effect size calculations showed that prucalopride 2 mg had a large effect (>0.8) on all PAC‐SYM items, including abdominal pain, abdominal discomfort, bloating, straining, and painful bowel movements. For abdominal symptoms and stool symptoms, effect sizes with prucalopride 2 mg were 1.3–2.3 times larger than those with placebo.Conclusions & Inferences: Prucalopride 2 mg q.d. for 12 weeks alleviates common constipation symptoms in women in whom laxatives had failed to provide adequate relief.Keywords
This publication has 18 references indexed in Scilit:
- Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation – Quality of Life questionnaire in prucalopride (RESOLOR®) trials for chronic constipationNeurogastroenterology & Motility, 2010
- Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12‐week, randomized, double‐blind, placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2008
- Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxativesGut, 2008
- Chronic constipation: a survey of the patient perspectiveAlimentary Pharmacology & Therapeutics, 2007
- Functional Bowel DisordersGastroenterology, 2006
- Review article: epidemiology and quality of life in functional gastrointestinal disordersAlimentary Pharmacology & Therapeutics, 2004
- Functional bowel disorders and functional abdominal painGut, 1999
- Quality of Life in Patients with Different Types of Functional ConstipationScandinavian Journal of Gastroenterology, 1997
- Constipation: a different entity for patients and doctorsFamily Practice, 1996
- Bowel Disorders Impair Functional Status and Quality of Life in the Elderly: A Population-Based StudyThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 1995